Ir para o conteúdo principal
Innate reports IPH4502 Phase 1 cancer data
Image for illustrative purposes only. Not a real photo.

Innate reports IPH4502 Phase 1 cancer data

Por

Pontos principais

  • Innate Pharma reported initial Phase 1 results for IPH4502, its experimental Nectin-4 antibody-drug conjugate, following a study involving 76 patients with advanced solid tumors.
  • The maximum tolerated dose was 3.6 mg/kg, with stomatitis the only dose-limiting toxicity and an objective response rate of 33% (2/6) in non-urothelial tumors at that dose.
  • Dose optimization is planned for the first half of 2027, focusing on patients with urothelial cancer whose disease progressed after enfortumab vedotin treatment.

Innate Pharma (NASDAQ:IPHA) reported initial Phase 1 results for IPH4502, its experimental Nectin-4 antibody-drug conjugate, in 76 patients with advanced solid tumors.

The study included 19 patients with urothelial cancer, all previously treated with enfortumab vedotin, with a median of three previous treatment lines in this group.

The maximum tolerated dose was 3.6 mg/kg every three weeks, with stomatitis the only dose-limiting toxicity; Grade 3 or higher treatment-emergent adverse events affected 43.4% of patients, including severe anemia in 11.8%.

Innate plans to begin dose optimization in post-enfortumab urothelial cancer during the first half of 2027.

At 3.6 mg/kg, the objective response rate reached 33% (2/6) among patients with non-urothelial tumors, while the urothelial cancer group recorded three partial responses and an unconfirmed disease control rate of 68.4% at intermediate doses.

IPH4502 combines a Nectin-4-targeting antibody with an exatecan chemotherapy payload, using a proprietary linker designed to deliver the drug to cancer cells, with low circulating free-exatecan levels observed during the study.


Perguntas frequentes